These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25403996)

  • 1. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis.
    Julià A; Ferrándiz C; Dauden E; Fonseca E; Fernández-López E; Sanchez-Carazo JL; Vanaclocha F; Puig L; Moreno-Ramírez D; Lopez-Estebaranz JL; Herrera E; de la Cueva P; Ávila G; Alonso A; Tortosa R; López-Lasanta M; Marsal S
    Pharmacogenomics J; 2015 Aug; 15(4):322-5. PubMed ID: 25403996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.
    Acosta-Colman I; Palau N; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Ballina J; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Canela-Xandri O; Alonso A; López Lasanta M; Tortosa R; Julià A; Marsal S
    Pharmacogenomics; 2013 May; 14(7):727-34. PubMed ID: 23651021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.
    Smith SL; Plant D; Lee XH; Massey J; Hyrich K; Morgan AW; Wilson AG; Isaacs J; Barton A
    Pharmacogenomics; 2016 May; 17(7):715-20. PubMed ID: 27180831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis.
    Julià A; Rodríguez J; Fernández-Sueiro JL; Gratacós J; Queiró R; Montilla C; Torre-Alonso JC; Pérez-Venegas JJ; Manrique-Arija S; Muñoz-Fernández S; González C; Roig D; Zarco P; Erra A; Castañeda S; García A; Salvador G; Díaz-Torne C; Blanco R; Domínguez AW; Mosquera JA; Vela P; Tornero J; Sánchez-Fernández S; Corominas H; Ramírez J; Avila G; Alonso A; Tortosa R; López-Lasanta M; Cañete JD; Marsal S
    Pharmacogenomics; 2014 Nov; 15(14):1763-1769. PubMed ID: 25493569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.
    Membrive-Jiménez C; Pérez-Ramírez C; Arias-Santiago S; Richetta AG; Ottini L; Pineda-Lancheros LE; Ramírez-Tortosa MDC; Jiménez-Morales A
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
    Lee YH; Ji JD; Bae SC; Song GG
    J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.
    Masouri S; Stefanaki I; Ntritsos G; Kypreou KP; Drakaki E; Evangelou E; Nicolaidou E; Stratigos AJ; Antoniou C
    Mol Diagn Ther; 2016 Jun; 20(3):221-5. PubMed ID: 27043841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis.
    Zeng Z; Duan Z; Zhang T; Wang S; Li G; Gao J; Ye D; Xu S; Xu J; Zhang L; Pan F
    Mod Rheumatol; 2013 May; 23(3):489-95. PubMed ID: 22760475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic prediction of the effectiveness of biologics for psoriasis treatment.
    Nishikawa R; Nagai H; Bito T; Ikeda T; Horikawa T; Adachi A; Matsubara T; Nishigori C
    J Dermatol; 2016 Nov; 43(11):1273-1277. PubMed ID: 27129929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
    Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.
    Coenen MJ; Toonen EJ; Scheffer H; Radstake TR; Barrera P; Franke B
    Pharmacogenomics; 2007 Jul; 8(7):761-73. PubMed ID: 17638513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.
    Prieto-Pérez R; Cabaleiro T; Daudén E; Abad-Santos F
    Pharmacogenomics J; 2013 Aug; 13(4):297-305. PubMed ID: 23337970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.